Frontera. The APEX in Gene Therapy Development.

Frontera is a leading clinical-stage biotechnology company that seeks to develop the best gene therapy medicines to improve the lives of patients across multiple disease areas.

Frontera's APEX Technology & Manufacturing Platform is an innovative adeno-associated virus (AAV) gene expression system. It includes novel and clinically validated AAV vectors, efficient and fully-integrated CMC processes, and access to early clinical data, making it possible to develop novel gene therapy products with quicker speed-to-market and lower cost.

  • World-class execution – leveraging fully integrated teams – across disease biology, gene therapy vector design, translational sciences, process and analytical development, in-house GMP manufacturing and clinical research.
  • State-of-the-art GMP facilities.
  • World-class and proven team in gene therapy R&D, having been in leading roles or as founders for some of the most successful and innovative gene therapy and gene editing products and companies.
  • Early access to clinical data made possible by Frontera’s unique scientific model.


Product development in gene therapy has historically focused on a limited number of rare monogenic disorders. The possibilities for gene therapy, however, are vastly greater. Frontera is realizing this potential with a pipeline that spans across not only orphan diseases, but also in larger patient markets – including Ophthalmology, Hematology, Cardiovascular and Metabolic Diseases.


World-Class R&D Team

Frontera's elite R&D team is made up of founders and scientific advisors from some of the most successful gene therapy development organizations around the world, bringing together the most advanced thinking in gene therapy, translational research, and biomanufacturing.

Scientific Advisory Board

Scientific Advisory Board

Philip Reilly, Ph.D.

Scientific Advisory Board

Glenn Pierce, Ph.D.

Scientific Advisory Board

Robert Kotin, Ph.D.

Scientific Advisory Board

Fraser Wright, Ph.D.

Scientific Advisory Board

George Church, Ph.D.

Scientific Advisory Board

Jean Bennett, M.D., Ph.D.

Scientific Advisory Board

Mark Kay, M.D., Ph.D.

Scientific Advisory Board

Xandra Breakefield, Ph.D.

Board of Directors

Wei Li, Ph.D.

Chairman, Founding Partner of Creacion Ventures

Carl Gordon, Ph.D.

Managing Partner, OrbiMed Advisors

David Wang, M.D., Ph.D.

Partner, OrbiMed Advisors

Ching Zhu, Ph.D.

Founding Partner of Creacion Ventures

Xinyan Li, Ph.D.

Co-Founder & CEO

Yanling Cao

Partner, Boyu Capital

Jiang Han

Managing Director, Sequoia Capital China

Management Team

The Frontera leadership team has broad experience  from their previous leadership roles in  global pharmaceutical companies as well as innovative biotech startups. The teams’ expertise spans from translational research and development of gene therapy products and biologics, GLP TOX studies, chemistry, manufacturing and Controls (CMC), clinical trial design and management, business development, new drug registration and commercialization.

Management Team

Xinyan Li, Ph.D.

Co-Founder & CEO

Management Team

Jasmine Gao

VP of Clinical Development

Management Team

Robert Lu, Ph.D.

Founder & VP of Technical Operations

Management Team

Allison Jia

VP of Finance



Recent News

Frontera Therapeutics Completes $160 Million Series B Financing to Fund Clinical Development and Manufacturing Capabilities

July 19, 2022

FDA clears Investigational New Drug (IND) application for lead gene therapy product candidate, FT-001, for the treatment of a rare inherited eye disease leading to severe visual impairment that may result in blindness. Investors in the $160 million Series B round include Boyu Capital, Sequoia China, and existing investors OrbiMed and Creacion Ventures, who were […]

Read More